

Referenzen:

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998;279:1200-5.
2. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. *Am J Med* 2000;109:87-94.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. *JAMA* 1997;277:301-6.
4. Davey AL, Britland A, Naylor RJ. Decreasing paediatric prescribing errors in a district general hospital. *Qual Saf Health Care* 2008;17:146-9.
5. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. *Pharmacoepidemiol Drug Saf* 2001;10:113-9.
6. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA* 1995;274:29-34.
7. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. *J Gen Intern Med* 2005;20:317-23.
8. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. *Pharm World Sci* 2002;24:46-54.
9. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. *Am J Emerg Med*. 1996 Sep;14(5):447-50.
10. M. Whirl-Carrillo, E. M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C. F. Thorn, R. B. Altman and T. E. Klein. „Pharmacogenomics Knowledge for Personalized Medicine“ *Clinical Pharmacology & Therapeutics* (2012) 92(4): 414-417.
11. CH van der Wouden, A Cambon-Thomsen, E Cecchin, KC Cheung, CL Davila-Fajardo, VH Deneer, V Dolzan, M Ingelman-Sundberg, S Jönsson, MO Karlsson, M Kriek, C Mitropoulou, GP Patrinos, M Pirmohamed, M Samwald, E Schaeffeler, M Schwab, D Steinberger, J Stingl, G Sunder-Plassmann, G Toffoli, RM Turner, MH van Rhenen, JJ Swen, and H-J Guchelaar on behalf of the Ubiquitous Pharmacogenomics Consortium. *Clinical Pharmacology & Therapeutics* (2017) 101(3): 341-358
12. M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. „Pharmacogenomics Knowledge for Personalized Medicine“ *Clinical Pharmacology & Therapeutics* (2012) 92(4): 414-417